FibroGen, Inc (FGEN) earnings
FGEN earnings moved a median of -6.12% by the close. Quarterly and annual FGEN reports and results, each read against the price at its own news timestamp. Back to the FGEN overview →
26 measured FGEN earnings events.
Where these FGEN earnings landedvs 21 measured FGEN earnings reactions
| Middle 50% of FGEN earnings reactions | -9.72% to -1.29% |
|---|---|
| Median reaction (to close) | -6.12% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 FGEN earnings events with a measured close landed between -9.72% and -1.29%; 19% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q KYNTRA BIO, INC. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q KYNTRA BIO, INC. For: Mar 31 | SEC filing · Form 10-Q | — | — | |
| Form 10-K KYNTRA BIO, INC. For: Dec 31 | SEC filing · Form 10-K | — | — | |
| FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | -9.72% | |
| Form 10-Q FIBROGEN INC For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -9.72% | |
| FibroGen to Report Third Quarter 2025 Financial Results | Press release | +0.00% | +0.00% | |
| FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +6.67% | — | |
| Form 10-Q FIBROGEN INC For: Jun 30 | SEC filing · Form 10-Q | +6.67% | — | |
| FibroGen to Report Second Quarter 2025 Financial Results | Press release | +1.87% | -1.29% | |
| FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -6.25% | -6.47% | |
| Form 10-Q FIBROGEN INC For: Mar 31 | SEC filing · Form 10-Q | -6.25% | -6.47% | |
| FibroGen to Report First Quarter 2025 Financial Results | Press release | +3.00% | -6.07% | |
| Form 10-K FIBROGEN INC For: Dec 31 | SEC filing · Form 10-K | -8.29% | -7.59% | |
| FibroGen Reports Third Quarter 2024 Financial Results | Press release | +3.88% | -18.10% | |
| Form 10-Q FIBROGEN INC For: Sep 30 | SEC filing · Form 10-Q | +3.88% | -18.10% | |
| FibroGen to Report Third Quarter 2024 Financial Results | Press release | -3.20% | -5.66% | |
| FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +3.25% | -6.12% | |
| Form 10-Q FIBROGEN INC For: Jun 30 | SEC filing · Form 10-Q | +3.25% | -6.12% | |
| FibroGen to Report Second Quarter 2024 Financial Results | Press release | -18.41% | -5.23% | |
| FibroGen Reports First Quarter 2024 Financial Results | Press release | -3.72% | +2.24% | |
| Form 10-Q FIBROGEN INC For: Mar 31 | SEC filing · Form 10-Q | -3.72% | +2.24% | |
| FibroGen to Report First Quarter 2024 Financial Results | Press release | -2.83% | +2.83% | |
| Form 10-K FIBROGEN INC For: Dec 31 | SEC filing · Form 10-K | +7.45% | +31.68% | |
| FibroGen Reports Third Quarter 2023 Financial Results | Press release | -3.55% | -13.69% | |
| Form 10-Q FIBROGEN INC For: Sep 30 | SEC filing · Form 10-Q | -3.55% | -13.69% | |
| FibroGen to Report Third Quarter 2023 Financial Results | Press release | -0.45% | -4.73% |
Keep exploring
More FGEN: analyst actions → · SEC filings → · FGEN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OASMIA PHARMACEUTICALS AB AMERICAN DEPOSITARY SHARE (OASM) | 223 | 0.00% | 35% |
| Atossa Therapeutics, Inc. (ATOS) | 222 | -0.02% | 48% |
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.